Goldman Sachs
NKGN

Goldman Sachs’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Goldman Sachs’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-365,000
Closed -$3.7M – 6141
2023
Q1 		$3.7M Hold
365,000
– – ﹤0.01% 3341
2022
Q4 		$3.63M Hold
365,000
– – ﹤0.01% 3460
2022
Q3 		$3.56M Hold
365,000
– – ﹤0.01% 3450
2022
Q2 		$3.54M Hold
365,000
– – ﹤0.01% 3516
2022
Q1 		$3.54M Hold
365,000
– – ﹤0.01% 3677
2021
Q4 		$3.53M Hold
365,000
– – ﹤0.01% 3747
2021
Q3 		$3.54M Buy
+365,000
New +$3.56M ﹤0.01% 3664

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Goldman Sachs's NKGN Position: Q2 2023 in Review

Goldman Sachs sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 365,000 shares — an estimated $3.7M sold.

Goldman Sachs first reported a position in NKGN in Q3 2021 and held it in 7 quarters. The position peaked at $3.7M in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • Goldman Sachs reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 365,000 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $3.7M.
  • Goldman Sachs first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • Goldman Sachs's NKGen Biotech, Inc. Common Stock position peaked at $3.7M in Q1 2023.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.